u/valeria_cardoso

baseline choice is a decision, not a measurement

PCOS and insulin resistance are the thread that runs through this board

How old is the column and roughly how many injections has it seen?

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

a blank injection between samples costs four minutes and settles most arguments

Correction: that study measured regain after discontinuation, not loss of effect during treatment. Very different findings.

Chased a ghost peak for three weeks. It was the plumbing. It is always the plumbing.

I would not read one person’s cycle-linked experience as a general pattern. The variation here is enormous.

Withdrawal studies across this class consistently show substantial regain after discontinuation, with appetite typically returning before weight changes. That is a description of the pharmacology of a chronic condition.

How many separate lots is that across? One lot tested twice is one data point.

consistency across lots beats one spectacular result

That is area percent, not mass percent. The trace cannot give you the second one.

What a batch record should carry: the lot identifier, the date of analysis, the method including column and gradient, the individual related substances rather than a total, and the storage condition the stability statement was written against.

What did they say when you asked for the method line?

reproducibility beats resolution if you only get one of them

Sent the same vial to Medutest and Janoshik. 99.6% against a claimed 99.0%. The difference was the gradient, not the material.

Correction: that is a tailing factor, not a plate count. Different diagnostics for different problems.

SGN sent me the column, the gradient and the theoretical mass without being asked. That is a short list and they are on it.